Ruben Boado received a PhD in biochemistry from the School of Pharmacy and Biochemistry, University of Buenos Aires (UBA), Argentina, in 1982. He completed a postdoctoral fellowship and conducted research as established investigator at the UBA Center for Nuclear Medicine. In 1985, Dr. Boado joined the UCLA School of Medicine with a grant from the Fogarty International Center, National Institutes of Health (NIH). He was appointed Visiting Research Endocrinologist in the UCLA Department of Medicine in 1988, Assistant Professor in 1991, Associate Professor in 1997, and Professor of Medicine in 2001.

At ArmaGen, Dr. Boado leads the molecular biology division, which is responsible for the genetic engineering, expression, and validation of novel recombinant fusion proteins, which cross the human blood-brain barrier (BBB). At UCLA, Dr. Boado's research program examined BBB genomics, and the genetic engineering of plasmid DNA for non-viral gene therapy for the brain.

He is a member of The Society for Neuroscience, and has authored more than 150 scientific journal articles and book chapters in his field. He has served on numerous scientific review committees including the US Department of Energy, the Alzheimer’s Association and the NIH. Dr. Boado is co-inventor of U.S. and European patents related to BBB drug delivery.